Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Gains from Sales and Divestitures (2017 - 2025)

Historic Gains from Sales and Divestitures for Altimmune (ALT) over the last 9 years, with Q3 2025 value amounting to $267903.0.

  • Altimmune's Gains from Sales and Divestitures fell 699.1% to $267903.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $267903.0, marking a year-over-year decrease of 699.1%. This contributed to the annual value of $288977.0 for FY2024, which is 15124.5% up from last year.
  • Per Altimmune's latest filing, its Gains from Sales and Divestitures stood at $267903.0 for Q3 2025, which was down 699.1% from $288977.0 recorded in Q4 2024.
  • Altimmune's 5-year Gains from Sales and Divestitures high stood at $288977.0 for Q4 2024, and its period low was $44778.0 during Q2 2022.
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $100642.0 (2023), whereas its average is $155477.3.
  • Per our database at Business Quant, Altimmune's Gains from Sales and Divestitures tumbled by 2201.51% in 2021 and then soared by 18973.45% in 2024.
  • Quarter analysis of 5 years shows Altimmune's Gains from Sales and Divestitures stood at $85413.0 in 2021, then decreased by 13.36% to $74000.0 in 2022, then surged by 55.43% to $115018.0 in 2023, then surged by 151.25% to $288977.0 in 2024, then dropped by 7.29% to $267903.0 in 2025.
  • Its last three reported values are $267903.0 in Q3 2025, $288977.0 for Q4 2024, and $288040.0 during Q3 2024.